These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9352962)

  • 1. Drug-induced cardiac arrhythmias: incidence, prevention and management.
    Doig JC
    Drug Saf; 1997 Oct; 17(4):265-75. PubMed ID: 9352962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug-induced ventricular tachycardia].
    Fauchier JP; Fauchier L; Babuty D; Breuillac JC; Cosnay P; Rouesnel P
    Arch Mal Coeur Vaiss; 1993 May; 86(5 Suppl):757-67. PubMed ID: 8267504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug induced arrhythmias].
    Usuda K
    Ryoikibetsu Shokogun Shirizu; 1996; (12):538-41. PubMed ID: 9047533
    [No Abstract]   [Full Text] [Related]  

  • 5. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
    Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
    J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs, QT interval abnormalities and ventricular arrhythmias.
    Thomas SH
    Adverse Drug React Toxicol Rev; 1994; 13(2):77-102. PubMed ID: 7918900
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?].
    Pelov R; Tankova L; Krushkov I
    Vutr Boles; 1999; 31(2-3):5-9. PubMed ID: 10847134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling.
    Vos MA; Crijns HJ
    Anadolu Kardiyol Derg; 2001 Mar; 1(1):27-34. PubMed ID: 12122969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-induced arrhythmias].
    Inoue H
    Nihon Rinsho; 1996 Aug; 54(8):2220-6. PubMed ID: 8810801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have clinical trials taught us about proarrhythmia?
    Skanes AC; Green MS
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
    Tran HT; Chow MS; Kluger J
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia?
    Krishnan SC; Galvin J; McGovern B; Garan H; Ruskin JN
    J Cardiovasc Electrophysiol; 1997 Sep; 8(9):1055-61. PubMed ID: 9300303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future.
    Layton D; Key C; Shakir SA
    Pharmacoepidemiol Drug Saf; 2003; 12(1):31-40. PubMed ID: 12616845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac arrest following treatment with non-cardiologic QT-interval-increasing medications].
    Al-Amood S; Elming H
    Ugeskr Laeger; 2005 May; 167(18):1966-8. PubMed ID: 15929273
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
    Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
    Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.